Fig. 1From: Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsProposed algorithm for the starting of PCSK9 inhibitors in very high-risk patients and in familial hypercholesterolemiaBack to article page